Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 pandemic. Our wo...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news
Yonsa (abiraterone acetate)
Title: Yonsa (abiraterone acetate)Category: MedicationsCreated: 10/2/2020 12:00:00 AMLast Editorial Review: 10/2/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 2, 2020 Category: Cancer & Oncology Source Type: news
Gut microbiome may influence how cancer patients respond to oral therapies, study suggests
(Lawson Health Research Institute) A new study from Lawson Health Research Institute and Western University illustrates how the gut microbiome interacts with an oral medication in prostate cancer patients, suggesting bacteria in the gut play a role in treatment outcomes. The findings, published in Nature Communications, highlight how the drug abiraterone acetate is metabolized by bacteria in the gut to reduce harmful organisms while promoting those that fight cancer. The team suspects this is one of many examples of how the microbiome influences our response to medications. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 29, 2020 Category: International Medicine & Public Health Source Type: news
Yonsa (Abiraterone Acetate Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 18, 2020 Category: Drugs & Pharmacology Source Type: news
Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic and save lives....
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news
Breakthrough discovery to transform prostate cancer treatment
(University of South Australia) A novel formulation of the prostate cancer drug abiraterone acetate - currently marketed as Zytiga - will dramatically improve the quality of life for people suffering from prostate cancer, as pre-clinical trials by the University of South Australia show the new formulation improves the drug's effectiveness by 40 per cent. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 20, 2020 Category: Biology Source Type: news
Dr Reddy's launches generic prostate cancer treatment drug in US
Pharma major Dr Reddy's Laboratories on Friday said it has launched generic Abiraterone Acetate tablets, used for treatment of prostate cancer, in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 18, 2020 Category: Pharmaceuticals Source Type: news
Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet needs continue...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Comorbid CVD May Up Mortality With ADT for Prostate Cancer
TUESDAY, Aug. 13, 2019 -- Elderly prostate cancer patients with preexisting cardiovascular diseases (CVDs) using abiraterone acetate (AA) or enzalutamide (ENZ) have higher short-term mortality compared with their counterparts without CVDs, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 13, 2019 Category: Pharmaceuticals Source Type: news
What Is the Ideal Glucocorticoid Regimen Combined With Abiraterone for Prostate Cancer?
Researchers compared several glucocorticoid regimens, given in combination with abiraterone acetate, for metastatic castration-resistant prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 5, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Final LATITUDE Results Confirm Previous Findings for High-Risk Prostate Cancer
Final results of LATITUDE confirm the beneft of abiraterone acetate plus prednisone along with ADT in high-risk metastatic castration-sensitive prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 7, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Abiraterone Risk Higher in Prostate Cancer Patients Who Have CVD Abiraterone Risk Higher in Prostate Cancer Patients Who Have CVD
A new analysis finds that men with prostate cancer treated with abiraterone acetate have a significantly higher mortality if they also have preexisting cardiovascular disease.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 6, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Zytiga May Up Mortality Risk in Prostate Cancer Patients With CVD
(MedPage Today) -- Increased hospitalizations seen among all abiraterone-treated patients (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 27, 2019 Category: Hematology Source Type: news
J & J Raises U.S. Prices on Around Two Dozen Drugs J & J Raises U.S. Prices on Around Two Dozen Drugs
Johnson& Johnson raised U.S. prices on around two dozen prescription drugs on Thursday, including the psoriasis treatment Stelara (ustekinumab), prostate cancer drug Zytiga (abiraterone) and blood thinner Xarelto (rivaroxaban), all among its top-selling products.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 14, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news
J & J raises U.S. drug prices
Johnson& Johnson raised U.S. prices on around two dozen drugs, including psoriasis treatment, Stelara, prostate cancer drug, Zytiga, and blood thinner, Xarelto. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 11, 2019 Category: Pharmaceuticals Source Type: news
